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BACKGROUND: The mechanism through which high- density lipoprotein (HDL) induces cardioprotection is not completely under-
stood. We evaluated the correlation between cholesterol efflux capacity (CEC), a functional parameter of HDL, and coronary 
collateral circulation (CCC). We additionally investigated whether A1BP (apoA1- binding protein) concentration correlates with 
CEC and CCC.
METHODS AND RESULTS: In this case- control study, clinical and angiographic data were collected from 226 patients (mean 
age, 58 years; male, 72%) with chronic total coronary occlusion. CEC was assessed using a radioisotope and J774 cells, and 
human A1BP concentration was measured using enzyme- linked immunosorbent assay. Differences between the good and 
poor CCC groups were compared, and associations between CEC, A1BP, and other variables were evaluated. Predictors of 
CCC were identified by multivariable logistic regression analysis. The CEC was higher in the good than in the poor CCC group 
(22.0±4.6% versus 20.2±4.7%; P=0.009). In multivariable analyses including age, sex, HDL- cholesterol levels, age (odds ratio 
[OR], 0.96; P=0.003), and CEC (OR, 1.10; P=0.004) were identified as the independent predictors of good CCC. These rela-
tionships remained significant after additional adjustment for diabetes mellitus, acute coronary syndrome, and Gensini score. 
The A1BP levels were not significantly correlated with CCC (300 pg/mL and 283 pg/mL in the good CCC and poor CCC 
groups, respectively, P=0.25) or CEC.
CONCLUSIONS: The relationship between higher CEC and good CCC indicates that well- functioning HDL may contribute to CCC 
and may be cardioprotective; this suggests that a specific function of HDL can have biological and clinical consequences.
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Coronary collateral circulation (CCC) is defined as arteriole- to- arteriole anastomoses that undergo expansion and remodeling in the setting of coro-
nary artery disease.1 Recurrent and severe myocardial 
ischemia is assumed to stimulate the development of 
coronary collaterals.2 It has been reported that clinical 
factors, including degree of coronary stenosis, lon-
ger duration of lesion occlusion, and heart rate can 
influence CCC.3 Several types of vascular cells, such 
as endothelial cells, monocytes, and smooth muscle 
cells, are known to participate in the process.4 Well- 
developed coronary collaterals may protect the at- risk 
myocardium and have been shown to lower the mor-
tality rate by 36%.5 Stimulation for the development of 
CCC is even considered a new therapeutic approach 
for ischemic heart disease.
High- density lipoprotein- cholesterol (HDL- C) levels 
have long been considered as a negative predictor 
of cardiovascular risk. In this regard, pharmacologi-
cal therapies elevating HDL- C levels were attempted, 
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but most studies did not obtain the expected benefit.6 
Lately, an individual’s cholesterol efflux capacity (CEC) 
beyond HDL- C levels has emerged as a negative pre-
dictor of cardiovascular outcomes.7
The mechanisms through which HDL induces 
cardioprotection include cholesterol efflux, inhibition 
of low- density lipoprotein oxidation, inhibition of vas-
cular inflammation or thrombosis, and promotion of 
angiogenesis.8 The effect of HDL on endothelial and 
other cells and eventually on angiogenesis has been 
investigated but not completely clarified.9 Although 
some animal studies demonstrated the angiogenic 
effect of HDL,10 the association between HDL- C 
levels and CCC was shown to be inconsistent.11,12 
Conversely, a recent study showed that A1BP 
(apoA1- binding protein) accelerates cholesterol efflux 
from endothelial cells and thereby regulates angio-
genesis.13 However, the role of CEC in development 
of CCC is poorly understood.
With the aforementioned gap in research, the aim 
of this study was to examine the association between 
CEC, a functional parameter of HDL, and CCC in pa-
tients with chronic total coronary occlusion, follow-
ing evaluation of the significance of the association 
by adjusting possible confounders. In addition, we 
investigated whether A1BP, an HDL- related protein 
known to influence cholesterol efflux, correlates with 
CEC and CCC.
METHODS
The data that support the findings of this study are 
available from the corresponding author upon reason-
able request.
Study Population
All consecutive patients who visited Severance 
Hospital and underwent coronary angiography from 
January 2001 to August 2009 were included in the 
database of the Cardiovascular Genome Center at 
Yonsei University College of Medicine, Seoul, Korea. 
The patients underwent coronary angiography for 
chest discomfort or pain. A total of 226 patients with 
chronic total occlusion of coronary arteries were in 
the database, and the study population consisted of 
these patients. The angiographic diagnosis was made 
based on findings showing total occlusion in at least 
1 epicardial coronary artery. This study complies with 
the Declaration of Helsinki and received proper ethical 
oversight. The Institutional Review Board of Severance 
Hospital, Seoul, Korea approved the research protocol 
(2020- 1453- 001). Written informed consent was ob-
tained from all study subjects.
Clinical and Angiographic Data Collection
Trained nurses obtained the clinical data, including 
demographic variables and medical history. Blood 
samples were collected from all study subjects at 
enrollment and stored at −80°C. In patients with 
acute coronary syndrome, coronary angiography 
was performed without delay after hospital visit. 
Blood samples were collected immediately before 
coronary angiography if the patient was fasting for 
more than 12  hours. In patients with a nonfasting 
state, blood samples were collected within 24 hours 
after angiography with 12- hour fasting. All patients 
received oral aspirin before angiography, and 5000 
U of intravenous heparin was used at the beginning 
of the procedure. The characteristics of coronary ar-
tery disease and collateral circulation were evaluated 
by 2 interventional cardiologists who were blinded to 
the other data of the patients. CCC was assessed 
according to the Rentrop classification as follows: 
grade 0, no filling; grade 1, filling of side branches via 
collateral channels without epicardial filling; grade 2, 
partial filling of the epicardial coronary artery via col-
lateral channels; and grade 3, complete filling of the 
epicardial coronary artery.14 If a patient had more 
than 1 collateral vessel, the highest collateral grade 
CLINICAL PERSPECTIVE
What Is New?
• Cholesterol efflux capacity was significantly 
higher in patients with good coronary collateral 
circulation (CCC) than in those with poor CCC.
• Younger age and higher cholesterol efflux ca-
pacity were identified as independent predic-
tors of good CCC after adjusting confounders 
such as high- density lipoprotein cholesterol.
What Are the Clinical Implications?
• Higher cholesterol efflux capacity indicating 
well- functioning high- density lipoprotein cho-
lesterol may be considered as a marker for 
good CCC.
• Cholesterol efflux capacity value predictive of 
good CCC can be a candidate of therapeu-
tic target for patients with ischemic vascular 
diseases.
Nonstandard Abbreviations and Acronyms
A1BP apoA1- binding protein
CCC coronary collateral circulation
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was selected. Then, the patients were classified 
according to their collateral grades as having poor 
(grade 0 or 1) or good (grade 2 or 3) CCC. Although 
analysis of collaterals with the Rentrop classification 
can be less accurate than analysis with the invasive 
pressure- or velocity- based collateral flow index,15 
this index was not available in our study subjects. 
However, because the Rentrop classification has 
often been used in several well- designed studies 
analyzing collaterals,14 we used this in the present 
study. The severity of coronary artery disease was 
assessed using the Gensini score, which quantifies 
disease severity by a point system based on lumi-
nal narrowing with a multiplier for specific lesion 
locations.16
Assessment of CEC and A1BP
The cholesterol efflux assay was performed using the 
following method: J774A1 cells (RRID: CVDL_0358; 
passage number 20– 29) were plated and radiolabeled 
with 2 μCi of 3H- cholesterol/mL for 24 hours. The cells 
were provided courtesy of Yury I Miller at University 
of California, San Diego, CA, USA. For the upregula-
tion of adenosine triphosphate- binding cassette trans-
porter subfamily member A1, cells were incubated with 
medium containing 0.2% bovine serum albumin and 
0.3  mmol/L 8- (4- chlorophenylthio)- cyclic adenosine 
monophosphate for 6 hours, as described previously.17 
The medium was then replaced with another medium 
containing 0.2% bovine serum albumin and the pa-
tients’ apolipoprotein- depleted serum for 4  hours.18 
The experiment was conducted by treating the cells 
with 2 mg/mL of an acyl- coenzyme A:cholesterol acyl-
transferase inhibitor. The cholesterol efflux propor-
tion was calculated using the following formula: CEC 
(%)={3H- cholesterol (μCi) in medium containing HDL/
[3H- cholesterol (μCi) in medium containing HDL+3H- 
cholesterol (μCi) in cells]}×100. We subtracted the 
background value from all sample values. The values 
were adjusted based on the CEC of the pooled serum 
that was run on each plate. Each sample was run in 
duplicate.
An enzyme- linked immunosorbent assay kit 
(MyBioSource, San Diego, CA, USA) was used 
to assay human A1BP in serum samples of study 
subjects. Assays were performed according to 
the manufacturer’s specification. Briefly, samples 
were incubated at 37°C for 90  minutes on capture 
antibody- coated plates. Detection antibody and 
horseradish peroxidase- conjugated antibody were 
then used to recognize retained A1BP. Chromogenic 
3,3′,5,5′- tetramethylbenzidine substrate was then 
added. The plates were read at an absorbance of 
450  nm. Appropriate specificity controls were in-
cluded, and all samples were run in duplicates.
Statistical Analysis
Continuous variables with normal distribution are pre-
sented as mean±SD, whereas those not meeting nor-
mality are presented as median (interquartile range). 
Categorical data are presented as frequencies and per-
centages. Differences between the 2 groups were com-
pared using the chi- square test for categorical variables. 
Continuous variables with normality were compared by 
Student’s t test, whereas those without normality were 
compared by Mann– Whiney U test. Pearson correlation 
analysis was used to evaluate the relationship between 
2 continuous variables. For the relationship between 
continuous and categorical variables, we used point- 
biserial correlation analysis. Predictors of CCC were 
identified by univariable logistic regression analysis. 
Those univariable factors with P values<0.05 and major 
relevant clinical factors (sex, diabetes mellitus, acute 
coronary syndrome, HDL- C, and Gensini score) were 
then entered into a multivariable analysis. We checked 
interactions between variables in multivariable model by 
using interaction terms. All analyses used 2- tailed tests 
with a significance level of 0.05. Statistical Package for 
the Social Sciences version 17.0 (SPSS Inc., Chicago, 
IL, USA) was used for all analyses.
RESULTS
Clinical Characteristics
The clinical and laboratory parameters of the 226 
study subjects are shown in Table  1. The patients’ 
mean age was 58  years, and male patients ac-
counted for 72% of the total population. Moreover, 
24% of the study population had diabetes mellitus, 
and 73% presented with acute coronary syndrome. 
Coronary angiography showed multivessel disease 
in 70% of study subjects. Patients with good CCC 
were likely to be younger (median age of 56  years 
and 61  years in the good and poor CCC groups, 
respectively; P=0.009). The CEC was higher in the 
good CCC group compared with the poor CCC 
group (22.0±4.6% and 20.2±4.7%, respectively; 
P=0.008). Values of other parameters including 
HDL- C and A1BP were comparable between the 2 
groups (Figure).
Correlation Between CEC, A1BP, and 
Other Variables
When analyzed in all subjects, CEC value showed a 
positive correlation with good CCC (r=0.18; P=0.008). 
Although CEC tended to be positively correlated with 
age and A1BP, the correlation was not statistically 
significant. It was not correlated with HDL- C levels or 
acute coronary syndrome (Table  2). Although A1BP 
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mellitus, smoking, and CEC, it was not statistically sig-
nificant (Table 2).
Predictors of Collateral Circulation
In the univariable logistic regression, age (odds ratio 
[OR], 0.97; P=0.017) and CEC (OR, 1.09; P=0.009) 
were significantly associated with good CCC. In a 
multivariable analysis model including age, male sex, 
HDL- C levels, and CEC, age (OR, 0.96; P=0.003), and 
CEC (OR, 1.10; P=0.004) were identified as independ-
ent predictors of good CCC. In particular, this signifi-
cant relationship was obtained after adjusting HDL- C 
levels. In a model additionally including diabetes mel-
litus, acute coronary syndrome, and the number of 
diseased vessels, the relationship remained significant 
(Table 3). We tested if there was interaction between 
CEC and acute coronary syndrome status using a 
multivariable model for good CCC. When we exam-
ined the interaction term, acute coronary syndrome x 
CEC, in a model, we found no significant interaction 
between the 2 variables (OR, 0.98; 95% CI, 0.83, 1.16; 
P=0.82). In addition, we checked for potential interac-
tion between key variables such as age, male sex, dia-
betes mellitus, acute coronary syndrome, HDL- C, and 
CEC. In the meantime, we found significant interaction 
between age and sex (P for interaction=0.015), and 
between age and acute coronary syndrome (P for in-
teraction=0.018). However, the predictive value of CEC 
remained significant (OR, 1.10; P=0.009) after taking 
into account these 2 interaction terms. Age and sex 
showed different predictive values in subgroups clas-
sified by sex and acute coronary syndrome (Table S1).
DISCUSSION
The major findings of this study are as follows: CEC 
was significantly higher in patients with good CCC than 
in those with poor CCC. Younger age and higher CEC 
were identified as independent predictors of good CCC 
in the multivariable analysis. The value of CEC was sig-
nificant after adjustment of HDL- C levels. Individuals’ 
A1BP level did not show correlations with CCC or CEC. 
To the best of our knowledge, our study is the first to 
demonstrate the link between CEC, a functional pa-
rameter of HDL, and CCC, the clinical presentation of 
angiogenesis in humans.
Previous studies have reported that CEC has a 
predictive value for cardiovascular outcomes. A pos-
itive association between CEC and cardiovascular 
risk has been suggested in high- risk populations.19 
On the contrary, most other studies have shown an 
inverse relationship between CEC and vascular risk 
Table 1. Clinical Characteristics of the Study Population
Good CCC (n=155) Poor CCC (n=71) P Value
Age, y 56 (48, 63) 61 (54, 65) 0.009
Male sex 109 (70.3) 54 (76.1) 0.37
Medical history
Diabetes mellitus 33 (21.3) 22 (31.0) 0.11
Hypertension 66 (42.6) 32 (45.1) 0.73
Smoking 28 (18.1) 16 (22.5) 0.43
Acute coronary syndrome 108 (71.1) 57 (82.6) 0.067
Body mass index, kg/m2 24.4 (22.7, 26.8) 24.1 (21.7, 26.5) 0.19
Laboratory values, mg/dL
Total cholesterol 181 (153, 207) 185 (150, 211) 0.89
Triglyceride 136 (94, 178) 131 (87, 195) 0.99
High- density lipoprotein- cholesterol 39 (33, 46) 40 (32, 47) 0.99
Low- density lipoprotein- cholesterol 110 (78, 135) 113 (76, 140) 0.88
Angiographic findings
Left main disease 7 (4.5) 4 (5.6) 0.98
1- vessel disease 46 (29.7) 21 (29.6)
2- vessel disease 46 (29.7) 18 (25.3) 0.46
3- vessel disease 63 (40.6) 31 (43.7)
Gensini score 68 (52, 87) 68 (48, 84) 0.46
Cholesterol efflux capacity, % 22.0±4.6 20.2±4.7 0.008
ApoA1- binding protein, pg/mL 266 (146, 399) 217 (124, 331) 0.25
Data are presented as means±SDs, numbers (%), or medians (interquartile ranges).
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or mortality in individuals with20 or without21 coronary 
artery disease. Moreover, additional biological func-
tions including angiogenesis, anti- inflammation, and 
antithrombosis were identified for HDL.8 However, ev-
idence regarding the effect of HDL function on clini-
cal results has been highly limited. Notably, our study 
showed the association between CEC and CCC in pa-
tients with chronic total coronary occlusion. Although 
we further examined whether A1BP, a possible con-
tributor to HDL activity, is associated with CCC, we 
could not find a significant association between A1BP 
and CCC.
HDL itself has angiogenic components. Vascular en-
dothelial growth factor receptor- 2 is activated by HDL, 
and this is mediated by sphingosine- 1- phosphate22 or 
scavenger receptor B- 1.23 Nitric oxide and adenosine 
triphosphate- binding cassette subfamily G member 
1 are known to participate in this process in vascular 
cells.9 We identified that CEC was a predictor for CCC, 
independent of HDL- C levels. In our study, the value of 
Table 2. Correlations Between CEC, A1BP, and Other Variables
CEC A1BP
r (95% CI) P Value r (95% CI) P Value
Age 0.12 (−0.01 to 0.25) 0.069 −0.10 (−0.26 to 0.06) 0.22
Male sex −0.04 (−0.17 to 0.09) 0.55 0.02 (−0.14 to 0.18) 0.78
Diabetes mellitus −0.06 (−0.19 to 0.07) 0.34 −0.15 (−0.30 to 0.01) 0.073
Hypertension −0.09 (−0.21 to 0.05) 0.20 −0.07 (−0.23 to 0.09) 0.37
Smoking −0.02 (−0.15 to 0.11) 0.76 0.15 (−0.01 to 0.30) 0.074
Acute coronary syndrome −0.04 (−0.18 to 0.09) 0.52 −0.04 (−0.20 to 0.13) 0.68
Body mass index 0.09 (−0.04 to 0.22) 0.16 −0.08 (−0.24 to 0.08) 0.33
Triglyceride 0.02 (−0.11 to 0.15) 0.79 0.04 (−0.12 to 0.20) 0.62
High- density lipoprotein- cholesterol 0.05 (−0.08 to 0.18) 0.42 0.05 (−0.11 to 0.21) 0.52
Low- density lipoprotein- cholesterol 0.04 (−0.10 to 0.16) 0.61 0.05 (−0.11 to 0.21) 0.53
Gensini score 0.57 (−0.07 to 0.190 0.39 0.01 (−0.15 to 0.17) 0.94
Good coronary collateral circulation 0.18 (0.05 to 0.30) 0.008 0.08 (−0.08 to 0.23) 0.35
CEC … … −0.15 (−0.31 to 0.01) 0.062
A1BP −0.15 (−0.31 to 0.01) 0.062 … …
A1BP indicates apoA1- binding protein; and CEC, cholesterol efflux capacity.
Figure. CEC and A1BP in patients with good or poor CCC.
The CEC was significantly higher in the good CCC group compared with the poor CCC group (A), 
whereas the A1BP levels did not differ between the 2 groups (B). A1BP indicates apoA1- binding 
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CEC was significant, whereas that of HDL- C was not. 
These findings can be possibly explained as follows. 
First, our study population had atherosclerotic cardio-
vascular disease, and the functionality of their HDL 
may not be intact. Therefore, CEC, which represents 
HDL functionality, rather than HDL- C levels, might have 
better shown the effects of HDL on CCC. Second, a 
prior study exhibited that HDL, in low levels, protected 
endothelial progenitor cells and promoted related an-
giogenesis. However, when the levels are high, HDL 
paradoxically impaired cell functioning and inhibited 
angiogenesis.24 Accordingly, HDL might not become 
an independent predictor in our study. Third, we could 
not rule out possible changes in cellular cholesterol 
concentration, or signal transduction by cholesterol ef-
flux might have affected CCC. Higher CEC is known to 
reduce cholesterol levels in the cell membrane.
When cholesterol is abundant in the endothelial cell 
membrane, membrane receptors are easily activated, 
and inflammation, cell proliferation, or angiogenesis 
can be promoted. In contrast, A1BP- mediated choles-
terol efflux decreases membrane cholesterol and in-
hibits angiogenesis.13 A1BP is known to enhance the 
overall binding of HDL to endothelial cells and simul-
taneously accelerate cholesterol efflux by lowering the 
binding affinity of HDL.25 A1BP was reported to reduce 
lipid rafts by cholesterol efflux,13 upregulate Notch sig-
naling, and impair vascular endothelial growth factor 
receptor 2 dimerization.26 To check whether A1BP, a 
protein related to both CEC and angiogenesis, could 
explain the findings, we performed A1BP assay in all 
samples from the study population. Nevertheless, no 
significant associations were identified between A1BP 
and CEC or CCC. A1BP secreted by surrounding tis-
sues worked as a negative regulator of angiogenesis.13 
However, the circulating A1BP levels analyzed in our 
study might not have sufficiently represented local 
A1BP activity and this needs to be clarified by further 
investigation. Interestingly, A1BP influences immune 
cells to inhibit the downstream signaling of toll- like re-
ceptor 427 and reduce vascular inflammation in mice.28 
Studying the influence of the anti- inflammatory effect 
of A1BP on the development of CCC may help reveal 
the possible role of A1BP.
Severity of coronary artery stenosis showed positive 
association with good CCC.29 Although we included 
the Gensini score as a parameter of disease severity, its 
association with CCC was not significant. Meanwhile, 
we analyzed associations between diabetes mellitus 
and cholesterol levels that may affect angiogenesis but 
did not find significant correlations in the current study. 
Gensini score did not show a significant correlation with 
CEC in our results. A previous study has shown a pos-
sible negative correlation between the value of CEC 
multiplied by HDL- C and number of diseased vessels. 
However, the conventional CEC value was not associ-
ated with disease severity.30 More studies are needed to 
provide a clear explanation on this relationship.
Our study has some limitations. First, it is difficult 
to make clear conclusions regarding cause- effect 
relationship between CEC and CCC based on our 
data. To our knowledge, however, the current results 
are the best available evidence on this study topic. 
Second, in study patients with acute coronary syn-
drome, CEC might be altered from that in patients 
with stable condition. In a previous study, patients 
with acute coronary syndrome showed lower levels 
of CEC compared with healthy controls.31 However, 
as shown in our analysis, there was no significant 
interaction between acute coronary syndrome and 
Table 3. Predictors of Good Coronary Collateral Circulation Identified by Multiple Logistic Regression







Age 0.97 (0.94– 0.99) 0.017 0.96 (0.93– 0.98) 0.003 0.96 (0.93– 0.99) 0.009
Male sex 0.75 (0.38– 1.40) 0.37 0.63 (0.31– 1.22) 0.18 0.64 (0.31– 1.30) 0.21
Diabetes mellitus 0.60 (0.32– 1.14) 0.12 0.72 (0.36– 1.42) 0.34
Hypertension 0.90 (0.51– 1.60) 0.73
Smoking 0.76 (0.38– 1.54) 0.43
Acute coronary syndrome 0.52 (0.24– 1.03) 0.070 0.54 (0.26– 1.15) 0.11
Body mass index 1.02 (0.97– 1.08) 0.39
Triglyceride 1.00 (0.99– 1.00) 0.99
High- density lipoprotein- cholesterol 1.01 (0.99– 1.03) 0.55 1.00 (0.99– 1.02) 0.81 1.00 (0.98– 1.02) 0.82
Low- density lipoprotein- cholesterol 1.00 (0.99– 1.01) 0.60
Gensini score 1.00 (0.99– 1.01) 0.51 1.01 (1.00– 1.02) 0.25
Cholesterol efflux capacity 1.09 (1.02– 1.16) 0.009 1.10 (1.03– 1.18) 0.004 1.09 (1.02– 1.17) 0.011
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CEC. Therefore, we can assume that the presence 
of acute coronary syndrome did not alter the rela-
tionship between CEC and CCC considerably. In ad-
dition, a larger study population might have helped 
draw firmer conclusions regarding our main findings. 
Nevertheless, the inclusion criteria of the present 
study were quite difficult to meet, and the size of 
our study population was the largest among similar 
studies. As mentioned earlier, our study is valuable 
because it is the first to show the association be-
tween CEC, a representative functional parameter of 
HDL, and CCC in clinical setting. Finally, the differ-
ence of CEC between patients with good and poor 
CCC was small (mean values of 22.0% and 20.2%; 
P=0.009). The differences of CEC (expressed as per-
centage) between cases and control groups in prior 
studies were similar in size: 11.8% and 10.4% in the 
report of Shao et al32 and 12.9% and 11.5% in that 
of Norimatsu et al.30 However, the predictive value of 
CEC (based on 1 SD change) on cardiovascular risk 
was robust (OR, 0.30; P=0.003) in the study by Shao 
et al. Likewise, when we assessed OR per 1- SD in-
crease in CEC, we found that higher CEC was asso-
ciated with higher probability of good CCC (OR, 1.57; 
P=0.004). This association remained significant after 
adjusting other confounders (OR, 1.51; P=0.011). 
Therefore, even though our intergroup difference in 
mean CEC was not large, this index may have poten-
tial of clinical utility.
In conclusion, the relationship between higher CEC 
and CCC suggests that well- functioning HDL may con-
tribute to the development of CCC and reduce cardio-
vascular risk. This important evidence shows that a 
specific function of HDL affects biological and clinical 
consequences. Although additional validation is re-
quired, higher CEC may be considered as a marker for 
good CCC, based on our results. Conversely, CEC value 
predictive of good CCC can be a candidate of therapeu-
tic target for patients with ischemic vascular diseases. 
Further studies are needed to develop optimal ways to 
enhance this specific HDL function.
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Table S1. Predictors of good CCC in subgroups classified by sex and acute coronary syndrome. 
 Males (n=163) Females (n=63) 
Acute coronary syndrome 
(n=165) 
No acute coronary 
syndrome (n=61) 
 
Odds ratio (95% 
CI) 
p 
Odds ratio (95% 
CI) 
p 
Odds ratio (95% 
CI) 
p 
Odds ratio (95% 
CI) 
p 
Age 0.98 (0.94, 1.01) 0.15 0.84 (0.74, 0.94) 0.004 0.98 (0.94 1,01) 0.16 0.75 (0.62, 0.91) 0.003 
Male sex -- -- -- -- 0.83 (0.37, 1.85) 0.65 0.11 (0.01, 0.86) 0.035 
Diabetes mellitus 0.62 (0.28, 1.38) 0.25 0.92 (0.19, 4.39) 0.92 0.73 (0.34, 1.59) 0.43 0.86 (0.12, 5.92) 0.88 
Acute coronary 
syndrome 
0.66 (0.27, 1.61) 0.36 0.43 (0.09, 2.07) 0.30 -- -- -- -- 
HDL-C 1.01 (0.98, 1.03) 0.63 0.99 (0.94, 1.05) 0.83 1.00 (0.98, 1.02) 0.76 0.94 (0.86, 1.03) 0.20 
Gensini score 1.00 (0.99, 1.01) 0.56 1.01 (0.99, 1.04) 0.30 1.00 (0.99, 1.01) 0.36 0.99 (0.96, 1.03) 0.58 
CEC 1.09 (1.01, 1.18) 0.025 1.09 (0.93, 1.27) 0.28 1.08 (1.00, 1.16) 0.044 1.26 (1.03, 1.55) 0.028 
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